Literature DB >> 28111778

Sporadic inclusion body myositis - a myodegenerative disease or an inflammatory myopathy.

C C Weihl1, A L Mammen2.   

Abstract

Sporadic inclusion body myositis (sIBM) is an insidious late-onset progressive myopathy that typically affects patients over the age of 50. Clinically, patients develop a characteristic pattern of weakness that affects the forearm flexors and knee extensors. Muscle biopsy, often utilized in the diagnosis, demonstrates a chronic myopathy with mixed pathologies harbouring intramyofiber protein inclusions and endomysial inflammation. The co-existence of these pathologic features (that is, inflammation and protein aggregation) has divided the field of sIBM research into two opposing (albeit slowly unifying) camps regarding disease pathogenesis. The present review explores the recent evidence supporting these distinct pathogenic mechanisms. Future therapies that are designed to target both aspects of sIBM pathologies will likely be necessary to treat sIBM.
© 2017 British Neuropathological Society.

Entities:  

Keywords:  myositis

Mesh:

Year:  2017        PMID: 28111778     DOI: 10.1111/nan.12384

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  9 in total

1.  Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series.

Authors:  Katarzyna Haczkiewicz; Agata Sebastian; Aleksandra Piotrowska; Maria Misterska-Skóra; Agnieszka Hałoń; Marta Skoczyńska; Maciej Sebastian; Piotr Wiland; Piotr Dzięgiel; Marzenna Podhorska-Okołów
Journal:  Rheumatol Int       Date:  2018-12-08       Impact factor: 2.631

Review 2.  Diagnostic Imaging of Inflammatory Myopathies: New Concepts and a Radiological Approach.

Authors:  Júlio Brandão Guimarães; Marcelo A Nico; Alípio G Omond; Laís Uyeda Aivazoglou; Rafael Baches Jorge; Edmar Zanoteli; Artur R C Fernandes
Journal:  Curr Rheumatol Rep       Date:  2019-02-14       Impact factor: 4.592

Review 3.  Which nonautoimmune myopathies are most frequently misdiagnosed as myositis?

Authors:  Andrew L Mammen
Journal:  Curr Opin Rheumatol       Date:  2017-11       Impact factor: 5.006

Review 4.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

Review 5.  New Developments in the Genetics of Inclusion Body Myositis.

Authors:  Kyla A Britson; Stephanie Y Yang; Thomas E Lloyd
Journal:  Curr Rheumatol Rep       Date:  2018-04-02       Impact factor: 4.592

6.  Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis.

Authors:  Kyla A Britson; Jonathan P Ling; Kerstin E Braunstein; Janelle M Montagne; Jenna M Kastenschmidt; Andrew Wilson; Chiseko Ikenaga; William Tsao; Iago Pinal-Fernandez; Katelyn A Russell; Nicole Reed; Tahseen Mozaffar; Kathryn R Wagner; Lyle W Ostrow; Andrea M Corse; Andrew L Mammen; S Armando Villalta; H Benjamin Larman; Philip C Wong; Thomas E Lloyd
Journal:  Sci Transl Med       Date:  2022-01-19       Impact factor: 19.319

7.  Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis.

Authors:  Leonardo Valente de Camargo; Mary Souza de Carvalho; Samuel Katsuyuki Shinjo; Acary Souza Bulle de Oliveira; Edmar Zanoteli
Journal:  Biomed Res Int       Date:  2018-01-29       Impact factor: 3.411

8.  A metastable subproteome underlies inclusion formation in muscle proteinopathies.

Authors:  Prajwal Ciryam; Matthew Antalek; Fernando Cid; Gian Gaetano Tartaglia; Christopher M Dobson; Anne-Katrin Guettsches; Britta Eggers; Matthias Vorgerd; Katrin Marcus; Rudolf A Kley; Richard I Morimoto; Michele Vendruscolo; Conrad C Weihl
Journal:  Acta Neuropathol Commun       Date:  2019-12-03       Impact factor: 7.801

9.  Muscle Transcriptomics Shows Overexpression of Cadherin 1 in Inclusion Body Myositis.

Authors:  Chiseko Ikenaga; Hidetoshi Date; Motoi Kanagawa; Jun Mitsui; Hiroyuki Ishiura; Jun Yoshimura; Iago Pinal-Fernandez; Andrew L Mammen; Thomas E Lloyd; Shoji Tsuji; Jun Shimizu; Tatsushi Toda; Jun Goto
Journal:  Ann Neurol       Date:  2022-02-11       Impact factor: 11.274

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.